What do we know about the new cholesterol pill, Lipfendra? Merck's new once-a-day drug gets FDA nod

FDA approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), the first oral PCSK9 inhibitor.

Lipfendra blocks the PCSK9 protein, enabling the liver to remove more LDL cholesterol; clinical trials show up to 60% LDL reduction.

List price is $315 for a 30-day supply, lower than injectable PCSK9 drugs which cost $500–$600 per month.

Injectable PCSK9 inhibitors have limited use due to cost and injection format; Lipfendra offers a more accessible oral alternative.

Heart disease remains the leading cause of death globally; physicians emphasize LDL lowering especially for heart attack or stroke patients.